Home / Market News / $CRL
benzinga Corporate Catalyst Impact 55/100 ● positive

Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions

Oct 13, 2026, 12:04 PM UTC · Primary ticker $CRL

Charles River Laboratories International announced a collaboration with Magellan Stem Cells to support the development and clinical advancement of stem cell-based therapies. This partnership leverages Charles River's expertise in biologics quality control and cGMP testing, aiming to drive innovation in regenerative medicine.

Charles River Laboratories International (CRL) has announced a partnership with Magellan Stem Cells, an Australian biotech firm. This collaboration positions CRL to provide critical testing and development support for Magellan's stem cell-based therapies, leveraging CRL's established expertise in biologics quality control and cGMP viral and release testing. This move is positive for CRL as it expands its footprint in the burgeoning cell therapy and regenerative medicine sector, potentially leading to new revenue streams and strengthening its position as a key service provider in advanced biopharmaceuticals. While not a major financial event, it signifies strategic growth and alignment with future trends in medicine, offering a long-term opportunity for CRL to capitalize on innovation in the biotech space.

$CRL positive New collaboration in growing field
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.